Slide 1: FolRα – Targeting ADC Phase 1 Potential Best-in-Class ADC for Ovarian and Endometrial Cancers
FolRα – Targeting ADC Phase 1 Potential Best-in-Class ADC for Ovarian and Endometrial Cancers STRO 002 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: STRO-002 Structure and Design
STRO-002 Structure and Design Optimized molecule provides potential for best-in-class STRO 002 STRO-002 Structure of hemiasterlin linker-warhead following conjugation STRO-002 is a novel homogeneous antibody drug conjugate using precisely positioned non-natural amino acids STRO-002 has a drug-antibo
Slide 4: Phase 1 Dose-Escalation Data Presented by Dr. Wendel Naumann
Phase 1 Dose-Escalation Data Presented by Dr. Wendel Naumann
Slide 5: Phase 1 Dose-Escalation Study of STRO-002 in Platinum-Resistant Ovarian Cancer
International Gynecologic Cancer Society Annual Meeting (Sept 10–13, 2020) Phase 1 Dose-Escalation Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant / Refractory Epithelial Ovarian Cancer (OC) R. Wendel Naumann1, Fadi S
Slide 6: Phase 1 Clinical Trial Design
Phase 1 Clinical Trial Design Fast Track FDA Registration Pathway Possible Based on Recent Precedents Key Objectives Part 1: Safety, MTD, RP2D, PK, ADA, preliminary efficacy Part 2: Response rates, duration of response, PFS, safety, PK STRO-002 Dose Level Dose Level Dose Level 5.2mg/kg 5.6mg/kg 6.4m
Slide 7: Heavily Pretreated Ovarian Cancer Patients: Demographics/Dose Levels
Heavily Pretreated Ovarian Cancer Patients: Demographics/Dose Levels Data as of August 31, 2020 Characteristic Total N = 39 (%) Age, median (range), years 61 (48-79) Tumor type EOC 30 (77) Fallopian tube 7 (18) Primary peritoneal 2 (5) ECOG PS 0 23 (59) 1 16 (41) Median time from diagnosis (range) 3
Slide 8: Generally Well Tolerated Without Ocular DLTs or SAEs
Generally Well Tolerated Without Ocular DLTs or SAEs Treatment Emergent AEs in ≥ 25% of Patients (without causality attribution) Treatment Emergent Adverse Events (TEAE) TEAE >20% Grade 1 Grade 2 Grade 3 Grade 4* N= 39 (%) Fatigue 7 (18) 16 (41) 4 (10) 27 (69) Nausea 15 (38) 9 (23) 24 (62) Neutropen
Slide 9: Robust Anti-Tumor Activity in Heavily Pre-Treated, Unselected Patients
Best % change in sum of target lesions from baseline Evaluable patients treated at ≥ 2.9 mg/kg, N=29 4 pts off study before post baseline scan 1 pt ongoing, not yet at first post baseline scan Data as of August 31, 2020 Robust Anti-Tumor Activity in Heavily Pre-Treated, Unselected Patients +30 +6 +1
Slide 10: Partial Response with 74% Tumor Reduction
Partial Response with 74% Tumor Reduction Patient Continues on Treatment Confirmed PR after 4 cycles Baseline 3/16/20 06/29/20 57-year-old woman with platinum resistant ovarian cancer progressing after 4 prior regimens received STRO-002 at 5.2 mg/kg and remains on study treatment
Slide 11: Long Duration on Study and Disease Control Observed
Long Duration on Study and Disease Control Observed in Unenriched, Heavily Pre-Treated Ovarian Cancer Patients Duration calculated as time from first dose to last dose given (on study) or date of PD (off study). Data as of Aug 31, 2020 STRO 002 0 5 10 15 20 25 30 35 40 45 50 55 60 2.9 mg/kg 2.9 mg/k
Slide 12: High Rates of CA-125 Responses are Associated with Anti-Tumor Activity
STRO 002 High Rates of CA-125 Responses are Associated with Anti-Tumor Activity *Gynecologic Cancer InterGroup (GCIG) criteria requires an elevated baseline CA-125 level of at least twice the upper limit of normal 10/25 (40%) have confirmed CA-125 reductions ≥ 50% that is maintained and confirmed 28
Slide 13: Promising Efficacy in a Heavily Pre-treated, Resistant/Refractory Population
Promising Efficacy in a Heavily Pre-treated, Resistant/Refractory Unenriched Patient Population Improved efficacy outcomes (increased ORR and DCR) observed as data matures with longer follow-up Overall response rate is 24% (8/33) High DCR of 60% at ≥ 12 weeks and 47% at ≥ 16 weeks Population not enr
Slide 14: Acknowledgements
Acknowledgements Our gratitude to the women who chose to participate in this study and their families Thank you to the STRO-002 - GM1 investigators and study staff for their diligence in caring for these patients
Slide 15: Summary and Next Steps
Summary and Next Steps Arturo Molina, MD, MS
Slide 16: STRO-002 Clinical Data Readout: April vs August Interim Analysis
CA-125 Reduction in level of ≥50% 57% (12/21) 72% (18/25) STRO-002 Clinical Data Readout April 20th, 2020 Interim Analysis August 31st, 2020 Interim Analysis N ≥ 2.9 mg/kg* 25 (20 evaluable) 34 (33 evaluable) Median Age 61 (47–76) 61 (48–79) Median Prior Lines 5 (2–10) 5 (2–10) Improved Efficacy Out
Slide 17: Summary and Next Steps in Clinical Development
STRO 002 Summary and Next Steps in Clinical Development STRO-002 is clinically efficacious at multiple doses, starting at 2.9 mg/kg Dose reductions or delays were not associated with loss of anti-tumor activity Further dose optimization will be explored during dose expansion Anticipate RP2D will be
Slide 18: FolRα – Targeting ADC Phase 1 Potential Best-in-Class ADC for Ovarian and Endometrial Cancers
FolRα – Targeting ADC Phase 1 Potential Best-in-Class ADC for Ovarian and Endometrial Cancers STRO 002